Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Galcanezumab in Migraine Prevention
NCT01625988Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2012
- Primary completion
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in migraine comparing LY2951742 with Placebo (2 arms). Primary endpoint: Mean Change From Baseline in the Number of Migraine Headache Days at 12 weeks. Started Jun 2012; status: completed.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT01625988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01625988.